economy
January 30, 2026
Eli Lilly looks to sharpen its domestic supply edge by building another U.S. plant
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
TL;DR
- Markets are moving lower, putting the S&P 500's positive week in jeopardy.
- Apple shares are down due to concerns about rising memory prices impacting future margins, despite strong quarterly performance and better-than-expected guidance.
- iPhone sales grew 23% year over year, the best result since the September 2021 quarter.
- Signs of stabilization are emerging in enterprise software-as-a-service stocks like Microsoft, CrowdStrike, and Palo Alto Networks after recent declines.
- Eli Lilly plans to invest over $3.5 billion in a new manufacturing facility in Pennsylvania's Lehigh Valley.
- The new facility will produce injectable medicines, including next-generation weight-loss therapies like retatrutide.
- Retatrutide showed significant weight loss in a Phase 3 study, averaging 28.7% body weight loss at 68 weeks.
- This investment is part of Eli Lilly's commitment of over $50 billion to boost U.S. manufacturing.
- The company's weight-loss drug portfolio includes Zepbound, the oral pill orforglipron, and retatrutide, targeting different patient needs.
- Many S&P 500 companies are scheduled to report earnings next week, including Eaton, Eli Lilly, Alphabet, Bristol Myers, Linde, and Amazon.
- The January non-farm payroll report is also due on Friday.
Continue reading the original article